Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation

1 Oct 2009

Abstract excerpt

The development of highly active antiretroviral therapy (HAART) to treat individuals infected with HIV-1 has dramatically improved patient outcomes, but HAART still fails to cure the infection. The latent viral reservoir in resting CD4+ T cells is a major barrier to virus eradication. Elimination of this reservoir requires reactivation of the latent virus. However, strategies for reactivating HIV-1 through...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19805909
DOI: 10.1172/jci39199

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activationPMID 19805909Read ↗

The SMAC Mimetic AZD5582 is a Potent HIV Latency Reversing AgentSemantic proximity Read ↗

A broad drug arsenal to attack a strenuous latent HIV reservoirSemantic proximity Read ↗

Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoirSemantic proximity Read ↗

Diversity of small molecule HIV‐1 latency reversing agents identified in low‐ and high‐throughput small molecule screensSemantic proximity Read ↗

Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing AgentsSemantic proximity Read ↗

Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells.Semantic proximity Read ↗

Dynamics of HIV Latency and Reactivation in a Primary CD4+ T Cell ModelSemantic proximity Read ↗

Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a CureSemantic proximity Read ↗

HIV latency: experimental systems and molecular modelsSemantic proximity Read ↗

Infection with a newly designed dual fluorescent reporter HIV-1 effectively identifies latently infected CD4+ T cellsSemantic proximity Read ↗

A New Small-Molecule Compound, Q308, Silences Latent HIV-1 Provirus by Suppressing Tat- and FACT-Mediated TranscriptionSemantic proximity Read ↗

The role of latency reversal in HIV cure strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.